Table 2.

V617F mutant allele load analyses in patients with PMF treated with JAK2 inhibitor (ruxolitinib)

		% JAK2V617F		Nominal allele burden change	p value (*p < 0.05)	Relative allele burden change	% JAK2V617F		Nominal allele burden change	p value (*p < 0.05)	Relative allele burden change
		Before JAK2 inhibitor therapy	During JAK2 inhibitor therapy				Before JAK2 inhibitor therapy	During JAK2 inhibitor therapy
1	2	0.61	0.03	− 0.58	0.0296*	95.1%	0.75	0.069	− 0.68	0.0025*	90.8%
2	22	55.45	42.92	− 12.53	0.0071*	22.6%	56.66	42.62	− 14.04	0.001*	24.8%
3	19	66.60	75.67	+ 9.07	0.0184*	13.6%	66.5	77.39	+ 10.89	0.0196*	16.4%
4	3	29.96	20.53	− 9.43	0.0106*	31.5%	36.46	21.47	− 14.99	0.0026*	41.1%
5	3	73.41	74.68	+ 1.27	0.665	1.7%	75.42	78.15	+ 2.73	0.0151*	3.6%
6	3	65.12	60.14	− 4.98	0.0016*	7.6%	68.98	62.32	− 6.66	0.0007*	9.6%